JPMorgan Upgrades Forbright to Overweight From Neutral, Adjusts Price Target to $22 From $23

Forbright, Inc. (FRBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Forbright, Inc. Reports Second Quarter 2026 Results Net interest income increased to $63.1 million Net interest margin increased to 3.19% Total loans grew to $6.1 billion Total deposits rose to $7.3 billion Credit trends remained favorable FOR IMMEDIATE RELEASE — CHE

Scotiabank upgraded Okta to Outperform ($165) and Datadog’s peer set (SentinelOne, Qualys, Tenable, Check Point) to Outperform; BofA upgraded T-Mobile to Buy ($220); HSBC upgraded Gilead to Buy ($155) and downgraded Allstate to Hold ($264) and Chubb to Hold. Bernstein downgraded Datadog to Market Perform ($226). Multiple other analyst rating changes and new coverages were issued across airlines, banks, retail, and energy.

Raymond James upgraded Hess Midstream Partners (HESM) to Outperform with a $32 price target, citing attractive valuation post-Chevron restructuring. The firm noted a 10.7% yield on expected 2027 distributions. HESM reported strong Q2 2026 earnings, but JPMorgan and Morgan Stanley downgraded it, citing contract and growth concerns. HESM trades at $30.04, near its 52-week low.

CoreWeave's financial troubles have halted data centre financing, with bond yields exceeding 16% and IPOs delayed. Banks are cautious due to rising rates, construction delays, and slowing demand. CoreWeave needs $85bn to fulfill $104bn in orders from Microsoft, Meta, and OpenAI, according to Bernstein. Industry executives note strong compute demand but tighter credit conditions.

Piper Sandler downgraded Globe Life (NYSE:GL) to Neutral, lowering its price target to $165 from $200 due to concerns over medical claims volatility. The stock trades at $168.41 with a P/E ratio of 10.97. Q3 results showed revenue of $1.6B, beating estimates, but EPS missed at $4.84. The firm cited exposure to medical claims severity and irregularity in Medicare supplement claims as key issues.

Moderna and MSD (Merck & Co) released early data for their melanoma vaccine, INTerpath-001, showing a 42% reduction in recurrence or death risk when combined with Keytruda. The study met expectations, with 82.2% recurrence-free survival at 24 months. Shares fell after a data leak but partially recovered. ESMO is investigating the breach. Analysts suggest potential billion-dollar sales if approved.